%0 Journal Article
%T CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study.
%A Rocca A
%A Giudici F
%A Donofrio CA
%A Bottin C
%A Pinamonti M
%A Ferrari B
%A Schettini F
%A Pineda E
%A Panni S
%A Cominetti M
%A D'Auria P
%A Bianchini S
%A Varotti E
%A Ungari M
%A Ciccarelli S
%A Filippini M
%A Brenna S
%A Fiori V
%A Di Mambro T
%A Sparti A
%A Magnani M
%A Zanconati F
%A Generali D
%A Fioravanti A
%J Cells
%V 13
%N 7
%D 2024 Mar 29
%M 38607036
%F 7.666
%R 10.3390/cells13070597
%X Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan-Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used (p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma.